𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A controlled clinical trial of baclofen as protective therapy in early huntington's disease

✍ Scribed by Dr. Ira Shoulson; Charles Odoroff; David Oakes; Jill Behr; David Goldblatt; Eric Caine; Judith Kennedy; Charlyne Miller; Kathryn Bamford; Allen Rubin; Sandra Plumb; Roger Kurlan

Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
872 KB
Volume
25
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A controlled trial of remacemide hydroch
A controlled trial of remacemide hydrochloride in Huntington's disease
✍ Dr. Karl Kieburtz; Andrew Feigin; Michael McDermott; Peter Como; David Abwender; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 450 KB 👁 1 views

## Abstract We conducted a randomized, double‐blind, placebo‐controlled tolerability study of a N‐methyl‐D‐aspartate (NMDA) glutamate receptor ion‐channel blocker, remacemide hydrochloride, in 31 independently ambulatory patients (18 men, 13 women) with Huntington's disease (HD). Subjects were rand

A controlled trial of fluoxetine in nond
A controlled trial of fluoxetine in nondepressed patients with Huntington's disease
✍ Dr. Peter G. Como; Allen J. Rubin; Chris F. O'Brien; Kathy Lawler; Charlyne Hick 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB 👁 1 views

## Abstract To examine the antidepressant specificity of fluoxetine in Huntington's disease (HD), we carried out a randomized, double‐blind, placebo‐controlled trial of this medication in nondepressed HD patients. Thirty patients with early HD who were not depressed (Hamilton Depression Inventory <

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

Double-blind, randomized, controlled tri
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
✍ Matthew B. Stern; Kenneth L. Marek; Joseph Friedman; Robert A. Hauser; Peter A. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 2 views

## Abstract Rasagiline (__N__‐propargyl‐1(__R__)‐aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase‐B inhibitor. This study was designed to evaluate the safety, tolerability, and preliminary efficacy of rasagiline monotherapy in early Parkinson's disease (PD) patients n

Whole-brain atrophy as a measure of prog
Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease
✍ Susie M.D. Henley; Edward J. Wild; Nicola Z. Hobbs; Chris Frost; David G. MacMan 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB 👁 1 views

## Abstract Therapeutic trials in Huntington's disease (HD) are challenging as clinical progression is slow and variable and reliable biomarkers are lacking. We used magnetic resonance imaging and the brain boundary shift integral to quantify whole‐brain atrophy rates over 1 year in early and prema